Clinical Trial Update: Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating LUM001 for reduction of pruritus in Alagille syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alagille Syndrome

Drugs mentioned

• LUM001

Snippet

Sponsor: Mirum Pharmaceuticals, Inc. | Conditions: Alagille Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2018-01-23